IBM Watson Health and OrbitalRX to Launch Integrated Solution to Assist Hospital Pharmacy Providers in Managing Drug Shortages

Joint offering pairs pharmacy supply chain management capabilities with evidence-based drug content, designed to help hospital pharmacy teams manage drug shortages CAMBRIDGE, Mass. and WINSTON-SALEM, N.C., Sept. 1, 2020 /PRNewswire/ — IBM (NYSE: IBM) Watson Health and OrbitalRX® today announced a strategic collaboration that aims to help address the emerging drug shortage crisis. The companies are combining OrbitalRX’s Drug Shortage Management Platform and IBM® Micromedex® into one unified solution called “OrbitalRX and Micromedex,” designed to create a single source for healthcare providers and pharmacy teams to access evidence-based treatment information alongside a hospital’s current drug inventory status and drug sourcing options. This one solution aims to quickly analyze the supply chain and identify clinical alternatives for drugs that are in short supply. The global drug shortage crisis has accelerated at an alarming rate during the COVID-19 crisis. According to the American Society of Health-Systems Pharmacists (ASHP), close to 200 drugs are currently on the drug shortage list in the U.S. alone. Management of these shortages is further complicated by the fact that shortages vary by drug and location, as noted by the American Medical Association (AMA). The new solution, OrbitalRX and Micromedex, will be designed to evaluate important drug information, clinical evidence, and comparative efficacy, alongside the hospital’s drug inventory, purchase history, and utilization data, enabling hospital providers, pharmacists and pharmacy technicians to proactively manage drug shortages. “As hospitals around the world experience shortages of life-saving therapies, there is an immediate, critical need for evidence-based information around clinical alternatives,” said Todd Nolen, General Manager, IBM Micromedex Solutions, IBM Watson Health. “We are addressing this critical need by combining our Micromedex content with powerful insights from the OrbitalRX platform. Our goal is to deliver a trusted platform to help pharmacists and other healthcare providers streamline workflow and rapidly respond to drug shortages with appropriate, safe and effective alternative therapies.” IBM Micromedex is one of the largest online reference databases for medication information. It is used by more than 4,500 hospitals and health systems worldwide to help support decision-making in medication therapy management, disease and condition management, toxicology, alternative medicine and patient education. OrbitalRX is the only platform designed by hospital pharmacists, for hospital pharmacists, to unify supply chain and clinical utilization to manage drug shortages and deliver the power of real-time situational awareness in hospital pharmacy workflows. “Patient safety can be compromised by supply chain interruptions, limited drug access due to high medication costs, and unforeseen events like COVID-19. OrbitalRX and Micromedex aim to help health system pharmacy departments mitigate these workflow challenges by identifying drug alternatives from a clinical and supplier perspective,” said OrbitalRX co-founder and CEO, Adam Orsborn, PharmD, MS. “Rooted in cloud-based technology and evidence-based insights, this new, unified solution is designed to deliver workflow efficiencies that will empower pharmacists and providers to prioritize therapeutic needs.”  “Hospital resources are scarcer than ever, especially with drug shortages and supply chain inefficiencies conspiring daily to upend the rigorous efforts of health systems to improve care quality while reducing cost,” said OrbitalRX co-founder and Chief Product Officer, Nate Peaty, PharmD, MS. “With these challenges in mind, OrbitalRX and Micromedex plan to provide health systems with a highly intelligent and automated solution designed to help them with one of the most frustrating issues they face today.”   OrbitalRX and Micromedex is anticipated to be available in Q4 2020. Please visit www.ibm.com/products/orbitalrx-micromedex.com to learn more about the solution, schedule a live demo, or to register for a webinar on September 24 to learn more. About IBM Watson HealthIBM Watson Health is a data, analytics, and technology partner for the health industry. Supported by the innovation of IBM and intelligence of Watson, we are committed to helping build smarter health ecosystems. Through the combination of our deep industry expertise in health, data and analytics, actionable insights, and reputation for security and trust, Watson Health is working together with its clients and partners to help them achieve simpler processes, better care insights, faster breakthroughs, and improved experiences for people around the world. Learn more at www.ibm.com/watson-health. For more information about IBM visit, www.ibm.com. Statements regarding IBM’s future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only.  About OrbitalRX Co-founded by health-system pharmacy leaders, OrbitalRX offers a one-of-a-kind drug shortage management platform which helps to identify risk factors using internal and external data for when a medication shortage could cause harm in your health-system. We offer everything you need to anticipate, evaluate, take action, follow-up, and report in a single, powerful platform designed to improve your overall shortage management strategy. To learn more about how we’re changing the way hospital pharmacies monitor their supply and manage shortages in the supply chain, visit www.orbitalrx.com.   IBM Media ContactMatthew Henson917-930-7147matthew.henson@ibm.com OrbitalRX Media Contact  Emily Nichols emily@orbitalrx.com SOURCE IBM Watson Health

Joint offering pairs pharmacy supply chain management capabilities with evidence-based drug content, designed to help hospital pharmacy teams manage drug shortages

CAMBRIDGE, Mass. and WINSTON-SALEM, N.C., Sept. 1, 2020 /PRNewswire/ — IBM (NYSE: IBM) Watson Health and OrbitalRX® today announced a strategic collaboration that aims to help address the emerging drug shortage crisis. The companies are combining OrbitalRX’s Drug Shortage Management Platform and IBM® Micromedex® into one unified solution called “OrbitalRX and Micromedex,” designed to create a single source for healthcare providers and pharmacy teams to access evidence-based treatment information alongside a hospital’s current drug inventory status and drug sourcing options. This one solution aims to quickly analyze the supply chain and identify clinical alternatives for drugs that are in short supply.

IBM Corporation logo. (PRNewsfoto/IBM)

The global drug shortage crisis has accelerated at an alarming rate during the COVID-19 crisis. According to the American Society of Health-Systems Pharmacists (ASHP), close to 200 drugs are currently on the drug shortage list in the U.S. alone. Management of these shortages is further complicated by the fact that shortages vary by drug and location, as noted by the American Medical Association (AMA).

The new solution, OrbitalRX and Micromedex, will be designed to evaluate important drug information, clinical evidence, and comparative efficacy, alongside the hospital’s drug inventory, purchase history, and utilization data, enabling hospital providers, pharmacists and pharmacy technicians to proactively manage drug shortages.

“As hospitals around the world experience shortages of life-saving therapies, there is an immediate, critical need for evidence-based information around clinical alternatives,” said Todd Nolen, General Manager, IBM Micromedex Solutions, IBM Watson Health. “We are addressing this critical need by combining our Micromedex content with powerful insights from the OrbitalRX platform. Our goal is to deliver a trusted platform to help pharmacists and other healthcare providers streamline workflow and rapidly respond to drug shortages with appropriate, safe and effective alternative therapies.”

IBM Micromedex is one of the largest online reference databases for medication information. It is used by more than 4,500 hospitals and health systems worldwide to help support decision-making in medication therapy management, disease and condition management, toxicology, alternative medicine and patient education. OrbitalRX is the only platform designed by hospital pharmacists, for hospital pharmacists, to unify supply chain and clinical utilization to manage drug shortages and deliver the power of real-time situational awareness in hospital pharmacy workflows.

“Patient safety can be compromised by supply chain interruptions, limited drug access due to high medication costs, and unforeseen events like COVID-19. OrbitalRX and Micromedex aim to help health system pharmacy departments mitigate these workflow challenges by identifying drug alternatives from a clinical and supplier perspective,” said OrbitalRX co-founder and CEO, Adam Orsborn, PharmD, MS. “Rooted in cloud-based technology and evidence-based insights, this new, unified solution is designed to deliver workflow efficiencies that will empower pharmacists and providers to prioritize therapeutic needs.” 

“Hospital resources are scarcer than ever, especially with drug shortages and supply chain inefficiencies conspiring daily to upend the rigorous efforts of health systems to improve care quality while reducing cost,” said OrbitalRX co-founder and Chief Product Officer, Nate Peaty, PharmD, MS. “With these challenges in mind, OrbitalRX and Micromedex plan to provide health systems with a highly intelligent and automated solution designed to help them with one of the most frustrating issues they face today.”  

OrbitalRX and Micromedex is anticipated to be available in Q4 2020. Please visit www.ibm.com/products/orbitalrx-micromedex.com to learn more about the solution, schedule a live demo, or to register for a webinar on September 24 to learn more.

About IBM Watson Health
IBM Watson Health is a data, analytics, and technology partner for the health industry. Supported by the innovation of IBM and intelligence of Watson, we are committed to helping build smarter health ecosystems. Through the combination of our deep industry expertise in health, data and analytics, actionable insights, and reputation for security and trust, Watson Health is working together with its clients and partners to help them achieve simpler processes, better care insights, faster breakthroughs, and improved experiences for people around the world. Learn more at www.ibm.com/watson-health.

For more information about IBM visit, www.ibm.com. Statements regarding IBM’s future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only. 

About OrbitalRX
Co-founded by health-system pharmacy leaders, OrbitalRX offers a one-of-a-kind drug shortage management platform which helps to identify risk factors using internal and external data for when a medication shortage could cause harm in your health-system. We offer everything you need to anticipate, evaluate, take action, follow-up, and report in a single, powerful platform designed to improve your overall shortage management strategy. To learn more about how we’re changing the way hospital pharmacies monitor their supply and manage shortages in the supply chain, visit www.orbitalrx.com.  

IBM Media Contact
Matthew Henson
917-930-7147
matthew.henson@ibm.com

OrbitalRX Media Contact 
Emily Nichols 
emily@orbitalrx.com

SOURCE IBM Watson Health

This post was originally published on this site



For enquiries, product placements, sponsorships, and collaborations, connect with us at hello@globalcloudplatforms.com. We'd love to hear from you!


Our humans need coffee too! Your support is highly appreciated, thank you!

Total
0
Shares
Previous Article

Now Go Build - Season 2

Next Article

IBM Study: Consumers' COVID-19 outlook, optimism and preferences vary greatly across generations and geographies

Related Posts

IBM To Accelerate Hybrid Cloud Growth Strategy And Execute Spin-Off Of Market-Leading Managed Infrastructure Services Unit

- New public company to launch as world's #1 Managed Infrastructure Services provider ARMONK, N.Y., Oct. 8, 2020 /PRNewswire/ -- IBM (NYSE: IBM) announced today it will accelerate its hybrid cloud growth strategy to drive digital transformations for its clients. Additionally, IBM will separate its Managed Infrastructure Services unit of its Global Technology Services division into a new public company ("NewCo"). This creates two industry-leading companies, each with strategic focus and flexibility to drive client and shareholder value. The separation is expected to be achieved as a tax-free spin-off to IBM shareholders, and completed by the end of 2021. "IBM is laser-focused on the $1 trillion hybrid cloud opportunity," said Arvind Krishna, IBM Chief Executive Officer. "Client buying needs for application and infrastructure services are diverging, while adoption of our hybrid cloud platform is accelerating. Now is the right time to create two market-leading companies focused on what they do best. IBM will focus on its open hybrid cloud platform and AI capabilities. NewCo will have greater agility to design, run and modernize the infrastructure of the world's most important organizations. Both companies will be on an improved growth trajectory with greater ability to partner and capture new opportunities – creating value for clients and shareholders."   "We have positioned IBM for the new era of hybrid cloud," said Ginni Rometty, IBM Executive Chairman. "Our multi-year transformation created the foundation for the open hybrid cloud platform, which we then accelerated with the acquisition of Red Hat. At the same time, our managed infrastructure services business has established itself as the industry leader, with unrivaled expertise in complex and mission-critical infrastructure work. As two independent companies, IBM and NewCo will capitalize on their respective strengths. IBM will accelerate clients' digital transformation journeys, and NewCo will accelerate clients' infrastructure modernization efforts. This focus will result in greater value, increased innovation, and faster execution for our clients." IBM, a Leading Hybrid Cloud and AI Company IBM will focus on its open hybrid cloud platform, which represents a $1 trillion market opportunity. Building on IBM's hybrid cloud foundation, the company acquired Red Hat to unlock the full value of the cloud for clients, further accelerating adoption of the platform. This platform facilitates the deployment of powerful AI capabilities to enable the power of data, application modernization services, and systems. These are all underpinned by the security, unmatched expertise in industry verticals, and deep commitment to open source innovation that clients expect from IBM. With tighter integration and focus on its open hybrid cloud and AI solutions, IBM will move from a company with more than half of its revenues in services to one with a majority in high-value cloud software and solutions. IBM will also have more than 50% of its portfolio in recurring revenues. IBM's open hybrid cloud platform architecture, based on RedHat OpenShift, works with the entire range of clients' existing IT infrastructures, regardless of vendor. This platform allows clients to "write-once/run-anywhere," and enables a hybrid cloud approach that drives up to 2.5 times more value for clients than a public cloud-only solution.  IBM's unique full-stack capabilities and large ecosystem of partners and ISV's deliver innovation and enable clients to unlock the full value of the hybrid cloud and their data.   IBM's software portfolio, focused on data and AI, automation, and security, enables the widest access to innovation through open source. IBM's business, strategy and technology consultants help clients transform by modernizing their existing applications, and by building new AI-infused data analysis capabilities on the leading open hybrid cloud platform. IBM's secure, mission-critical public cloud is designed to provide all required regulatory controls, and offers clients a foundation of open source software, security leadership, and enterprise-grade infrastructure. IBM's Systems business, integrated with the hybrid cloud platform, allows cloud-native developers to capitalize on the unique capabilities of IBM's hardware. Leveraging its long-term relationships with clients, IBM will continue to drive the innovation in hardware that enterprises rely on for their most mission-critical computing needs. As part of this strategic acceleration, IBM is taking action to simplify and optimize its operating model for speed and growth. This includes streamlining its geographic model and transforming its go-to-market structure to better engage with and support clients. IBM is also continuing to consolidate its shared services. This simplified and focused operating model will support accelerated innovation for the hybrid cloud, and provide more flexibility to increase investment in growth areas. The result will be an enhanced financial profile with a clear trajectory for improved revenue and profit growth. NewCo, the Leading Managed Infrastructure Services Company The new company (to be named at a subsequent date) will immediately be the world's leading managed infrastructure services provider. It has relationships with more than 4,600 technology-intensive, highly regulated clients in 115 countries, including more than 75% of the Fortune 100, a backlog of $60 billion, and more than twice the scale of its nearest competitor. The new company will be entirely focused on managing and modernizing client-owned infrastructures, a $500 billion market opportunity. It will leverage its unrivaled expertise to offer hosting and network services, services management, infrastructure modernization, and migrating and managing multi-cloud environments. These are critical services that are core to client operations. With a streamlined business model, NewCo will create value by helping enterprises optimize their performance through AI and automation. NewCo's services will enable enterprises to build agility and efficiency into their infrastructure and datacenters. NewCo will be able to better modernize infrastructures for an unparalleled roster of clients in all industries, with relationships that have been built over decades. NewCo will extend its leadership through increased investment in the next generation of transformational managed infrastructure services, with more opportunity for margin expansion, profit growth and cash generation.    NewCo will also be able to partner fully across all cloud vendors, opening new avenues for growth, while maintaining a strong strategic partnership with IBM and continuing to serve existing and new clients. Separation Transaction Details The proposed separation is expected to be effected through a pro-rata spin-off to IBM shareowners that will be tax-free for U.S. federal income tax purposes. The transaction is subject to customary closing conditions, including Form 10 registration with the U.S. Securities and Exchange Commission, receipt of a tax opinion from counsel, and final approval by IBM's Board of Directors. The separation is currently expected to be completed by the end of 2021.  Following separation, the companies together are initially expected to pay a combined quarterly dividend that is no less than IBM's pre-spin dividend per share. Following the completion of the separation, each company's dividend policy will be determined by its respective Board of Directors. One-time transaction costs are expected to include tax charges, operational separation activities, and other customary items. J.P. Morgan Securities LLC and Lazard are serving as financial advisors for the transaction, with Paul, Weiss, Rifkind, Wharton & Garrison LLP acting as legal advisor. Preliminary Third-Quarter Results In connection with today's announcement, IBM is providing preliminary financial results for the third quarter ended September 30, 2020. IBM expects to report revenue of $17.6 billion, GAAP diluted earnings per share from continuing operations of $1.89, and operating (non-GAAP) earnings per share of $2.58. As IBM is currently in its normal financial closing process, these are approximate figures and are subject to revision until IBM reports its full third-quarter results as planned later this month. Investor webcast details IBM will host an investor webcast beginning at 8 a.m EDT, Thursday, October 8, 2020. The Webcast may be accessed via a link at https://www.ibm.com/investor/events/ibm-strategic-update-2020   About IBMFor more information about IBM, visit ibm.com/news. Contacts Media:Jonathan Adashek+1 202-528-7479jonathan.adashek@ibm.com Sarah Meron+1 347-891-1770Sarah.meron@ibm.com Edward Barbini+1 914-499-6565barbini@us.ibm.com Investor Relations:Patricia Murphy+1 914-499-5800pamurphy@us.ibm.com Forward-Looking and Cautionary Statements Except for the historical information and discussions contained herein, statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the company's current assumptions regarding future business and financial performance. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including, but not limited to, the following: a downturn in economic environment and client spending budgets; the company's failure to meet growth and productivity objectives; a failure of the company's innovation initiatives; damage to the company's reputation; risks from investing in growth opportunities; failure of the company's intellectual property portfolio to prevent competitive offerings and the failure of the company to obtain necessary licenses; cybersecurity and data privacy considerations; fluctuations in financial results; the possibility that the proposed separation of the Managed Infrastructure Services unit of the company's Global Technology Services will not be completed within the anticipated time period or at all, the possibility of disruption or unanticipated costs in connection with the proposed separation or the possibility that the separation will not achieve its intended benefits; impact of local legal, economic, political, health and other conditions; adverse effects from environmental matters, tax matters and the company's pension plans; ineffective internal controls; the company's use of accounting estimates; impairment of the company's goodwill or amortizable intangible assets; the company's ability to attract and retain key employees and its reliance on critical skills; impacts of relationships with critical suppliers; product quality issues; impacts of business with government clients; currency fluctuations and customer financing risks; impact of changes in market liquidity conditions and customer credit risk on receivables; reliance on third party distribution channels and ecosystems; the company's ability to successfully manage acquisitions, alliances and dispositions, including integration challenges, failure to achieve objectives, the assumption of liabilities, and higher debt levels; legal proceedings and investigatory risks; risk factors related to IBM securities; and other risks, uncertainties and factors discussed in the company's Form 10-Qs, Form 10-K and in the company's other filings with the U.S. Securities and Exchange Commission (SEC) or in materials incorporated therein by reference. Any forward-looking statement in this release speaks only as of the date on which it is made. Except as required by law, the company assumes no obligation to update or revise any forward-looking statements. The financial information for the quarter ended September 30, 2020 is based on the company's internal management accounts and reporting as of and for the 2020 third quarter. The company has not yet completed its financial statement review procedures for the 2020 third quarter. The preliminary results of operations are subject to revision as the company prepares its financial statements and disclosure for the 2020 third quarter, and such revisions may be significant. As a result, the final results and other disclosures for the 2020 third quarter may differ materially from this preliminary data. This preliminary financial data should not be viewed as a substitute for all financial statements prepared in accordance with U.S. GAAP.

IBM Brings Artificial Intelligence At Scale To The Marketing And Media Industry

Expanding AI Advertising Suite to Strengthen Brand, Publisher and Consumer Value Exchange in a Privacy-Forward Future NEW YORK, Oct. 5, 2020 /PRNewswire/ -- IBM (NYSE: IBM) today announced three new products to add to its growing suite of AI solutions for brand and publishers. The new capabilities are privacy-forward and designed to allow brands to reach consumers while considering user privacy. IBM intends to work with industry leaders, including Xandr/AT&T, Magnite, Nielsen, MediaMath, LiveRamp and Beeswax to help scale the use of AI across the industry. The announcement was made this morning at Advertising Week's digital-first virtual event #AW2020. "While the advertising industry strives to re-emerge strong from the global economic and societal issues we faced this year, it's also deep in the throes of a major transformation with changes to mobile identity, certain elimination of third-party cookies, compliance and regulatory shifts and increased demand for trust and transparency," said Bob Lord, SVP, Cognitive Applications and Blockchain, IBM. He added: "We believe AI will be the 'backbone' of the new era as the industry prepares for the next generation of advertising. We're using AI to help solve problems across the advertising industry, just like IBM has in countless other industries like Healthcare, Financial Services and Retail. Our work will be a step forward in our evolution to meet the advertising industry's upheaval, and we are proud to help the advertising industry advance with the value of AI." The IBM Watson Advertising suite of solutions leverages AI to help clients make informed, data-based decisions. Expanding on recent additions to the suite, including Watson Advertising Accelerator, Watson Advertising Social Targeting with Influential and Watson Advertising Weather Targeting among others, the planned AI-enabled capabilities include: Extensions for IBM Watson Advertising Accelerator: Enhanced video and OTT capabilities available in the coming months that are expected to leverage Watson Machine Learning, to help enable marketers to pivot video advertising creative based on individual user reaction.  IBM Watson Advertising Attribution: Beta Solution available in the coming months that leverages Watson Machine Learning, which allows marketers to accurately quantify the efficacy of their advertising spend while understanding intent and performance drivers. IBM Watson Advertising Predictive Audiences: Solution leverages Watson Discovery, to help enable marketers to progress beyond 'look-alike' to 'do-alike' segments in a privacy-forward format to reach consumers that exhibit similar behaviors.    A New Ecosystem to Accelerate AI Adoption and in Advertising IBM plans to bring its toolset to industry leaders including Xandr/AT&T, Magnite, Nielsen, MediaMath, LiveRamp and Beeswax to help make it accessible across the advertising ecosystem. The companies will have an opportunity to drive the next generation of IBM advertising technologies to help reinstate trust in the marketplace. IBM Watson can offer increased AI capabilities for businesses across language, automation and trust. The planned capabilities from IBM Watson Advertising will be designed to help infuse trust and transparency into the advertising ecosystem. IBM is negotiating definitive agreements with Xandr/AT&T and Magnite. "We're currently leveraging IBM's AI through The Weather Channel, an approach that helps us use data to create meaningful and respectful experiences with consumers in the moments they need us most," said Rand Harbert, Executive Vice President and Chief Agency, Sales & Marketing Officer, State Farm. "IBM has evolved from an advertising partner to an AI partner, enabling us to help our customers and prospective customers better prepare and respond during life events." "The advertising industry is undergoing rapid change and we're infusing AI into our platform to better equip independent publishers in a sea of walled gardens," said Tom Kershaw, CTO, Magnite. "We're proud to stand with IBM, a company rooted in advanced technology, to deliver on the promise of an open web and solve the mounting challenges facing independent publishers."  "Across WPP, we are committed to helping our clients navigate the disruptive trends that have been building for some time," said John Dunleavy, Global President, Eightbar. "We've seen firsthand the important role AI can play in mitigating bias and making data useful so that every constituent - brands, content owners and most importantly consumers - can have authentic, relevant and meaningful interactions." "The opportunities for AI are immense--and we're already seeing real value within the retail and consumer packaged goods (CPG) industry," said Arun Ramaswamy, Chief Technology Officer, Global Consumer Business, Nielsen. "AI algorithms have vast potential to reinvigorate the brand-consumer trust dynamic by leveraging mathematical techniques that remove biases in the data consumers provide before they lead to improper results and interpretations. And within an open, cloud-based ecosystem, having the right, robust, high-quality data fueling AI is paramount to better understand and predict purchasing habits, and thereby inform marketing and advertising efforts." "AI technologies are transforming organizations and freeing up employees to do higher-value work," said Victoria Petrock, Principal Analyst, Emerging Technology, Insider Intelligence. "For marketers and advertisers, AI is already disrupting core functions, including ad targeting, media buying, content creation and propensity modeling." "Data is the key to increasing engagement across platforms that deliver premium content," said Grant Ries, SVP of Marketplaces & Emerging Business at LiveRamp. "We're thrilled to connect our Marketplace with IBM AI to deliver actionable insights, at scale, across the ecosystem in order to help partners thrive in an undefined future. As the digital marketing industry evolves, it's more essential than ever to rely on trusted partners to preserve the integrity of the open web." "AI is no longer an emerging technology, it's here, now and the digital ecosystem must lean in to realize its full value beyond media buying and selling," said David Cohen, CEO, IAB. "I am thrilled to see IBM, with its deep roots in artificial intelligence, take on a leadership role to develop CTV and attribution solutions for the next generation marketplace." "It's in our DNA to empower our clients and partners with the tools to establish deep and trusted connections with consumers at scale," said Joe Zawadzki, founder and CEO, MediaMath. "As inveterate champions of the power of math and science in marketing, we are eager to usher in a new era of enterprise applications into our industry and are excited to expand our partnership with IBM to introduce their world-class capabilities to an open web that keenly needs them." "We're thrilled to help power IBM Watson Advertising with our Bidder-as-a-Service™ platform," said Ari Paparo, Co-Founder & CEO, Beeswax. "It's exciting to help IBM Watson unlock AI-driven, predictive dynamic creative for more relevant advertising that gets smarter over time." "As a company that has been integrating IBM Watson into our platform for over five years, our team at Influential has seen, firsthand, how crucial AI is in identifying the right influencers, targeting audiences, and delivering content at scale," said Ryan Detert, Chief Operating Officer, Influential. Statements regarding IBM's future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only.  About IBM Watson:Watson is IBM's AI technology for business, helping organizations to better predict and shape future outcomes, automate complex processes, and optimize employees' time. Watson has evolved from an IBM Research project, to experimentation, to a scaled set of products that run anywhere. With more than 30,000 client engagements, Watson is being applied by leading global brands across a variety of industries to transform how people work. To learn more, visit: https://www.ibm.com/watson. Contact:Megan Levinsonmegan.levinson@ibm.com SOURCE IBM